(Reuters) -AnaptysBio said on Wednesday it would end the development of its eczema drug after it failed to meet the main and secondary goals of a mid-stage trial.
The company’s shares were halted during premarket trade.
The drug, ANB032, did not meet the primary goal of the proportion of patients who achieved at least a 75% improvement from baseline on an eczema severity index.
The company will focus on the rest of its autoimmune portfolio, which includes drugs for rheumatoid arthritis and a type of inflammatory bowel disease, CEO Daniel Faga said in a statement.
(Reporting by Puyaan Singh in Bengaluru; Editing by Sriraj Kalluvila)
Comments